Provectus Announces Publication of Updated Data from Metastatic Neuroendocrine Phase 1 PV-10® Study at American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program
June 01, 2020 07:00 ET
|
Provectus Biopharmaceuticals Inc.
Treatment refractory, immunologically cold, hepatic tumor type50% reduction of treated disease; 83% stabilization of overall patient disease (RECIST)Median progression-free survival not reached (by CT...
Provectus Announces PV-10® STING Agonist Abstract at American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting II
May 18, 2020 09:00 ET
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, May 18, 2020 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today is pleased to announce the publication of an abstract about and data from ongoing preclinical study of investigational...
Provectus Announces Acceptance of PV-10® Liver Cancer Abstracts at American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program
April 29, 2020 16:30 ET
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, April 29, 2020 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today is pleased to announce that abstracts about and data from our clinical trials of investigational autolytic cancer...
Provectus Announces PV-10® Liver Cancer Presentation in ePoster Gallery of Society of Interventional Radiology (SIR) 2020 Annual Scientific Meeting
April 16, 2020 17:30 ET
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, April 16, 2020 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today said that data from its clinical trial of autolytic cancer immunotherapy PV-10 (rose bengal disodium) as a...
PV-10® Abstract Previously Accepted for Presentation at Terminated American Association for Cancer Research (AACR) Annual Meeting 2020
March 17, 2020 08:00 ET
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, March 17, 2020 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today said that data from ongoing research into investigational lysosomal-targeting cancer immunotherapy PV-10 (rose bengal...
Provectus Announces Presentation of Preliminary Results from Phase 1 Trial of PV-10® (rose bengal disodium) for Treatment of Metastatic Uveal Melanoma at ESMO I-O Congress 2019
December 12, 2019 08:00 ET
|
Provectus Biopharmaceuticals Inc.
13 patients treated to date have received single-agent PV-10 or combination of PV-10 and standard of care checkpoint blockadeIndependent safety profiles of PV-10 and checkpoint inhibition were...
Provectus Announces Presentation of Initial Results from Phase 1B Trial of PV-10® in Combination with KEYTRUDA® for Treatment of Checkpoint-Refractory Advanced Melanoma at SMR 2019 Congress
November 21, 2019 10:19 ET
|
Provectus Biopharmaceuticals Inc.
First 10 checkpoint-refractory melanoma patients treatedEstablished safety profiles of PV-10 and KEYTRUDA were maintained20% ORR and 40% DCR (RECIST 1.1)Changes in immune system activation biomarkers...
Provectus Announces Presentation of Updated Results from Phase 1B Trial of PV-10® in Combination with KEYTRUDA® for Treatment of Checkpoint-Naïve Advanced Melanoma at SMR 2019 Congress
November 21, 2019 09:00 ET
|
Provectus Biopharmaceuticals Inc.
Full accrual of 21 checkpoint-naïve melanoma patientsNo safety concerns identified; no significant overlap of toxicities95% 12-month OS rate; 100% 12-month DSS rate; Median PFS of 11.7 months10% CR...
Provectus Announces Acceptance of PV-10® Poster Presentations at ESMO Immuno-Oncology Congress 2019
October 24, 2019 07:00 ET
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, Oct. 24, 2019 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that data from an ongoing clinical trial of lysosomal-targeting, cancer immunotherapy PV-10 (rose bengal...
Provectus Announces Acceptance of PV-10 Poster Presentations at SMR 2019 Congress
September 24, 2019 09:00 ET
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, Sept. 24, 2019 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that data from an ongoing clinical trial of lysosomal-targeting cancer immunotherapy PV-10® in combination...